AlphaQuest LLC Acquires 1,261 Shares of Pulse Biosciences, Inc $PLSE

AlphaQuest LLC boosted its holdings in Pulse Biosciences, Inc (NASDAQ:PLSE) by 68.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,116 shares of the company’s stock after purchasing an additional 1,261 shares during the quarter. AlphaQuest LLC’s holdings in Pulse Biosciences were worth $50,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its stake in Pulse Biosciences by 98.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock worth $29,000 after purchasing an additional 838 shares during the period. PNC Financial Services Group Inc. bought a new position in Pulse Biosciences in the 1st quarter worth approximately $90,000. GAMMA Investing LLC boosted its stake in Pulse Biosciences by 2,203.1% in the 1st quarter. GAMMA Investing LLC now owns 6,034 shares of the company’s stock worth $97,000 after purchasing an additional 5,772 shares during the period. Farther Finance Advisors LLC boosted its stake in Pulse Biosciences by 24.6% in the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company’s stock worth $143,000 after purchasing an additional 1,778 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Pulse Biosciences by 27.1% in the 4th quarter. Wells Fargo & Company MN now owns 11,315 shares of the company’s stock worth $197,000 after purchasing an additional 2,416 shares during the period. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Stock Performance

NASDAQ:PLSE opened at $15.17 on Friday. The stock’s fifty day moving average is $15.50 and its 200 day moving average is $16.41. Pulse Biosciences, Inc has a fifty-two week low of $13.77 and a fifty-two week high of $25.00. The firm has a market capitalization of $1.02 billion, a PE ratio of -14.45 and a beta of 1.68.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Insiders Place Their Bets

In other Pulse Biosciences news, CTO Darrin Uecker sold 15,000 shares of the stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $16.40, for a total value of $246,000.00. Following the sale, the chief technology officer owned 137,872 shares in the company, valued at $2,261,100.80. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 71.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Separately, Oppenheimer began coverage on Pulse Biosciences in a research note on Monday, July 7th. They issued an “outperform” rating and a $22.00 price target for the company. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $22.00.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.